B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35731887.
- Also identified by DOI 10.1126/scitranslmed.abn3353 and PMC identifier 9284935.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptor (CAR) T cell therapies targeting CD19 and CD22 have been successful for treating B cell cancers, but CAR T cells targeting non-B cell cancers remain unsuccessful. We propose that rather than being strictly a side effect of therapy, the large number of CAR interactions with normal B cells may be a key contributor to clinical CAR T cell responses.
Medical subject headings
- Drug-Related Side Effects and Adverse Reactions
- Immunotherapy, Adoptive